1. Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.
- Author
-
Yadav PK, Verma S, Chauhan D, Yadav P, Tiwari AK, Saklani R, Gupta D, Rana R, Shah AA, Verma S, Naresh K, Gayen JR, and Chourasia MK
- Subjects
- Humans, Female, Chromatography, Liquid methods, Breast Neoplasms drug therapy, Animals, Nanoparticles chemistry, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Liquid Chromatography-Mass Spectrometry, Paclitaxel pharmacokinetics, Paclitaxel administration & dosage, Bortezomib pharmacokinetics, Bortezomib administration & dosage, Bortezomib chemistry, Tandem Mass Spectrometry methods
- Abstract
Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines. Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher C
max for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ). Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.- Published
- 2024
- Full Text
- View/download PDF